Navigation Links
Hard to Treat Diseases, Inc. (HTDS) Attorney Brad Essman Uncovers Reports of Retail Brokers Making False Statements

TORONTO, Sept. 16 /PRNewswire-FirstCall/ - Attorney Bradley Essman, acting on behalf of Hard to Treat Diseases, Inc. (HTDS) ( has uncovered irregularities in the actions of certain retail brokers who restricted trading in HTDS and LSDR stock.

The investigation of these matters is sponsored by Investor Relations firm Mina Mar Group, again acting aggressively protect its client companies. Mina Mar is currently suing a stock chat board and certain anonymous posters who make fraudulent "stock bashing" statements.

"We have received reports from our shareholders that certain retail brokers refused to accept buy orders in our securities and told our shareholders that the Depository Trust Clearing Corporation (DTC) mandated this action. However, DTC's legal chief told me personally that DTC is not authorized to take such action."

"This raises several burning questions: (1) what is the real reason such actions were taken, (2) how do these brokers have the authority to do this, (3) were these brokers acting in collusion, (4) who profited from this action, and (5) why are these brokers lying to their clients?"

"We plan on getting to the bottom of this situation in short order," said Mr. Essman.

Mr. Essman is an international business attorney and former Assistant State Attorney of Hillsborough County (Tampa), Florida, where he served with the Special Prosecutions Unit for Economic and White Collar Crimes. His has offices in Tarpon Springs and St. Petersburg, Florida.

Mr. Essman is investigating why certain retail brokers restricted trading in the securities of HTDS and LDSR.

Mina Mar President Miro Zecevic said, "Our clients are viable, revenue-producing companies with substantial assets. The more you look at them now, the more you can easily see that they have great potential for the future. We will never allow them to be desecrated by financial parasites, like naked short sellers, stock bashers and manipulators. We intend to investigate these matters thoroughly to see if there is any wrong doing. Our actions cause you to understand just how much we protect our clients."

HTDS and LDSR shareholders who have information concerning these issues or who wish to make reports on these matters are strongly urged to contact We are especially interested in statements and written communications to our shareholders and other investors from retail brokers concerning trading restrictions and in collecting reports of investors being stopped from trading in our securities. We intend to investigate any and all allegations of manipulation and naked short selling.

In other company news, HTDS this morning filed its Adequate Disclosure documents to comply with Pink Sheets request to remove the "Skull and Bones" icon and ranking. The company will be posting the actual decision of Pink Sheets as a Filing on Pink Sheets for its shareholders and followers review. Pink Sheets is of the opinion that "a news release was put out by the company itself, talking about a "5 cent target" price for its stock by the CEO which was followed by an increase in trading volume" which justifies a down grade in ranking.

Pursuant to the issuer's news release of September 14, 2009, the issuer wishes to direct attention to the following link:

More updates to follow shortly.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact; For any corporate matters, please contact

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
2. Shockwave Treatment May Not Be Best for Shoulder Pain
3. Premion First in Australia to Treat Cancer Patients with RapidArc(R) Radiotherapy Technology from Varian Medical Systems
4. Weighing costs, benefits of HIV treatments
5. The Lustgarten Foundation Says Patrick Swayzes Death Highlights the Need for Increased Research into Early Diagnosis and Treatment of Pancreatic Cancer
6. Hard To Treat Diseases (HTDS) - CUSIP Change to Force Short Sellers To Cover
7. Particle Beam Radiation Therapy Promising But Unproven for Treating Cancer
8. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
9. Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production
10. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
11. Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: